Qty: 100μL Rabbit anti-UBE1L Catalog No. 38-4301 Lot No. Rabbit anti-UBE1L

FORM This polyclonal antibody is supplied as a 100 µL aliquot of neat antiserum containing 0.1% sodium azide..

PAD: ZMD.376

IMMUNOGEN Synthetic peptide derived from the C-terminal region of the human UBE1L (-activating enzyme E1-like ).

SPECIFICITY This antibody reacts with the human UBE1L protein. On Western blots, it identifies a single band at ~110 kDa.

REACTIVITY Reactivity has been confirmed with Ube1L-transfected COS-7 cell lysates.

Sample Western Immuno- Immuno- ELISA Blotting histochemistry histochemistry (frozen) (paraffin) Human +++ +++ +++ ND Immunogen ND ND ND +++ (Excellent +++, Good++, Poor +, No reactivity 0, Not applicable N/A, Not Determined ND)

USAGE Working concentrations for specific applications should be determined by the investigator. Appropriate concentrations will be affected by several factors, including secondary antibody affinity, antigen concentration, sensitivity of detection method, temperature and length of incubations, etc. The suitability of this antibody for applications other than those listed below has not been determined. The following dilutions are recommended starting points for this product.

Western Blotting: 1:500 Immunohistochemistry (frozen and paraffin): 1:5000 ELISA: 1:500

STORAGE Store at 2-8°C for up to one month. Store at –20°C for long-term storage. Avoid repeated freezing and thawing.

(cont’d)

www.invitrogen.com Invitrogen Corporation • 1600 Faraday Avenue • Carlsbad • CA 92008 • Tel: 800.955.6288 • E-mail: [email protected] PIN:31684 Rev. 7/07 DCC-06-0084 Copyright 2005, Zymed Laboratories (38-4301 cont’d)

BACKGROUND UBE1L has high sequence identity with the ubiquitin-activating enzyme UBE1, and it has been identified as the activating enzyme for the ubiquitin-like protein interferon stimulated 15 kDa (ISG15).1 UBE1L is readily induced in acute promyelocytic leukemia (APL) by the chemotherapeutic agent all-trans-retinoic acid.2 Over-expression of UBE1L caused APL cell death and degradation of the oncogenic protein promyelocytic leukemia (PML)/retinoic acid receptor alpha (RARα).2 UBE1L promoter mediates transcriptional response to RA in a retinoid receptor-selective manner. PML/RARα, a repressor of RA target , abolishes this UBE1L promoter activity. UBE1L has also been implicated in potentiating interferon signaling3 and is a potential ling cancer tumor suppressor as UBE1L expression is repressed in lung cancer cell lines.4 UBE1L is also found in normal human lung epithelium.

REFERENCES 1. Yaun W & Krug RM. EMBO J 20(3):362-371, 2001. 2. Kitareewan S, et al. PNAS 99(6):3806-3811, 2002. 3. Malakhova OA, et al. Genes Dev 17(4):455-460, 2003. 4. McLaughlin PM, et al. Int J Cancer 85(6):871-876, 2000.

RELATED PRODUCTS

Product Conjugate Cat. No. Protein A Sepharose® 4B 10-1041 rec-Protein G Sepharose® 4B 10-1241

ZyMAX™ Goat x Rabbit IgG ZyMAX™ Goat x Mouse IgG Conjugate (H+L) (H+L) Purified 81-6100 81-6500 FITC 81-6111 81-6511 TRITC 81-6114 81-6514 Cy™3 81-6115 81-6515 Cy™5 81-6116 81-6516 HRP 81-6120 81-6520 AP 81-6122 81-6522 Biotin 81-6140 81-6540

Zymed® and ZyMAX™ are trademarks of Zymed Laboratories Inc. Cy™ and Sepharose® are trademarks of Amersham Biosciences Ltd.

For Research Use Only MZ040626

www.invitrogen.com Invitrogen Corporation • 1600 Faraday Avenue • Carlsbad • CA 92008 • Tel: 800.955.6288 • E-mail: [email protected] PIN:31684 Rev. 7/07 DCC-06-0084 Copyright 2005, Zymed Laboratories